Biotechnology company developing precision immunotherapies for autoimmune diseases
Biotechnology company developing precision immunotherapies for autoimmune diseases. Its lead antibody program, HSB-101, selectively depletes TRBV9-positive T cells for axial spondyloarthritis and related HLA-B27-mediated conditions, aiming to preserve healthy immune cells and achieve durable disease remission through an immune reset. The pipeline includes additional therapies targeting specific immune-cell subsets.